a16z：AI 如何改写接近 20 亿美元的新药研发经济学
a16z 拆了一笔账：一款新药现值成本接近 20 亿美元、平均 13 年才能上市。文章讲清 AI 在分子筛选、临床试验设计、患者招募三个环节分别能省多少时间，适合关注医药投资或 AI 落地方向的人。
a16z 发布分析指出，一款新药从研发到上市平均耗时 13 年，把各阶段失败候选药物的成本摊销后，单个新药研发的现值成本接近 20 亿美元。临床试验成本的持续上涨进一步压缩了药企的研发产出效率。
文章认为 AI 可以从多个环节改善这些经济学指标：识别有前景的分子、设计临床试验方案、提升患者招募效率。这些改进一方面能提高研发成功率，另一方面能缩短开发周期，两者共同作用于降低单位新药的综合成本。
对行业的直接影响是，药企可能因此去追求那些按现有成本结构原本不划算的治疗靶点和适应症。a16z 的判断是 AI 会把制药行业做得更大，而不是取代它。
Developing a drug takes years, and most candidates never reach patients. Amortizing the cost of failed drugs across stages, the present value cost of developing a drug is close to $2B. The process takes 13 years on average, with rising clinical trial costs putting further pressure on R&D productivity. AI could improve those economics by increasing the probability of success and reducing development time, from identifying promising molecules to designing clinical trials and improving patient recruitment. That may enable companies to pursue therapeutic targets and indications that might otherwise have been uneconomical. Full piece on why AI will make pharma even bigger: a16z.news/p/big-pharma-c… Alex Immerman @aleximm x.com/i/article/2121… 🔗 View Quoted Tweet📊 7 ⚡
This report is categorized under AITOP's "Industry" desk, focusing on US frontier AI labs and Silicon Valley technology leaders. Within our cross-regional analytical framework, it directly maps to AI developer toolchains, coding agents, and engineering workflows. Key entities and technical topics under continuous tracking include a16z, AI drug discovery, drug discovery, clinical trials.
Source attribution: curated from a16z (@a16z).
